Jefferies resumed coverage on Pacific Biosciences with a new price target
$PACB
Biotechnology: Laboratory Analytical Instruments
Industrials
Jefferies resumed coverage of Pacific Biosciences with a rating of Buy and set a new price target of $4.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/11/2024 | Buy → Neutral | UBS | |
| 6/3/2024 | $4.00 | Buy | Jefferies |
| 4/22/2024 | Overweight → Neutral | JP Morgan | |
| 4/18/2024 | $7.00 → $2.50 | Buy → Neutral | Goldman |
| 12/14/2023 | $11.00 | Overweight | Stephens |
| 12/14/2023 | Neutral | Guggenheim | |
| 12/13/2023 | Peer Perform | Wolfe Research | |
| 11/17/2023 | $13.00 → $10.00 | Neutral → Buy | UBS |
8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)
SD - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)
DEFA14A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)
4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)
4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)
4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)
UBS downgraded Pacific Biosciences from Buy to Neutral
Jefferies resumed coverage of Pacific Biosciences with a rating of Buy and set a new price target of $4.00
JP Morgan downgraded Pacific Biosciences from Overweight to Neutral
4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)